Page 229 - Drug Class Review
P. 229
Drug Effectiveness Review Project
Drugs Authors: Wilcock et al. 53 Country: Multinational (Canada, Finland, France, Germany, Norway, Sweden, Netherlands, UK) Janssen Research Foundation To evaluate the efficacy and safety of GAL in the treatment of AD Setting: Multi-center (86) Sample size: 653 randomized (525 completed) placebo galantamine galantamine N/A 32 mg/d 24 mg/d 6 months 6 months 6 months 215 218 220 Probable AD according to the NINCDS; MMSE score of 11-24; ADAS-Cog score > 12; FAST ≤ 6 at Had no responsible caregiver; neurogenerative disorder; multi-infarct dementia or clinically active C
Alzheimer Year: 2000 Study design: RCT baseline ChE inhibitor cognitive evaluation
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
